Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Operating expense | 65M | 7.8% |
| Net Income | -60M | 0.3% |
Balance Sheet (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 508M | 7.4% |
| Total Liabilities | 123M | 3.1% |
| Total Equity | 385M | 8.7% |
| Shares Outstanding | 219M | 3.8% |
Cash Flow (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | -53M | 44.2% |
| Cash from financing | 14M | 143.6% |
EPS
Financial Highlights for Allogene Therapeutics in Q1 '25
Operating Expenses for this period were 65M, showing a 7.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -60M, showing a 0.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics. Higher operating expenses might indicate increased investments or potential inefficiencies.
